TIL cell therapy for brain glioma after standard treatment fails
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests a treatment made from your tumor’s immune cells (TILs) to help shrink brain glioma. You may be considered if your glioma is back or has spread and standard options are no longer working (or don’t exist).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and expected to live more than 3 months
- You have a confirmed brain glioma that is newly diagnosed, recurring, or has spread
- Your performance is fairly good (Karnofsky 60%+ or ECOG 0–2)
- You must have a place where doctors can safely take tissue for biopsy/surgery, or fluid where TILs can be taken
- Recent blood tests must meet minimum levels for white cells, platelets, hemoglobin, and liver/kidney function
- You must stop other cancer treatments (radiation/chemo/biologics) at least 28 days before the TIL collection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for advanced brain cancers like glioma and meningioma. It combines your own immune cells (tumor-infiltrating lymphocytes or TILs) with an immunotherapy drug (pembrolizumab) to help your body fight the tumor. It's for people who have tried other treatments without success or have no standard options left.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
This trial tests GC101 tumor-infiltrating lymphocytes (TILs), which are special immune cells collected from a tumor, grown in a lab, and given back to treat gastrointestinal cancers that have returned or spread. It may help your immune system better attack the cancer, especially when standard treatments have not worked.
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.